Liver / Gastrointestinal Cancer Clinical Trials

Phase II Trial of Perioperative CV301 Vaccination in Subjects with Colorectal Cancer that has Metastasized to the Liver

The study aims to:

- Determine if vaccination with CV301 in combination with Nivolumab in addition to perioperative systemic chemotherapy and surgical resection improves overall survival as compared to Nivolumab alone with perioperative chemotherapy and surgical resection in patients with hepatic-limited metastatic colorectal cancer.
- Compare recurrence free survival between the experimental and control treatment groups.
- Evaluate the response rates (both by RECIST and surgical pathology) between the experimental and control groups.

Learn more about this trial

NCI/CTEP #10139: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

The study aims to:
Clinical Trial Spotlight

Phase 2 Study of ONC201 in Recurrent or Metastatic Type 2 Endometrial Cancer

The purpose of this study is to test the safety and effectiveness for an investigational compound known as ONC201. Previous laboratory research has shown that ONC201 uses a novel mechanism that induces a stress response to kill endometrial cancer cells but not normal cells. Those with metastatic or recurrent Type 2 endometrial cancer who failed one or more prior chemotherapy regimen(s) are eligible to participate, although other criteria must also be met.

Learn more about this trial

Other Available Trials

Breast
Genitourinary
Gynecologic
Hematologic Oncology
Melanoma
Pediatric
Phase I
Prostate
Thoracic

Assess the progression free survival (PFS) of patients receiving atezolizumab monotherapy and cobimetinib in combination with atezolizumab for unresectable cholangiocarcinoma.

Assess the overall survival (OS) of patients receiving cobimetinib in combination with atezolizumab and atezolizumab monotherapy for unresectable cholangiocarcinoma.

Determine the objective response rate (ORR), defined as complete plus partial response, of cobimetinib in combination with atezolizumab and atezolizumab monotherapy in patients with unresectable cholangiocarcinoma.

Determine the relationship between PD-L1 expression in tumor at baseline and on treatment, and response to treatment.

Assess the safety and tolerability of cobimetinib in combination with atezolizumab and atezolizumab monotherapy in patients with unresectable cholangiocarcinoma.

Learn more about this trial

M15-916: A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

The study aims to:

 Determine the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RPTD) of ABBV-176.

 Assess the pharmacokinetic profile of ABBV-176.

Learn more about this trial

A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination with PD-1 Blocking Antibodies

The study aims to:

 Determine the safety of trigriluzole in combination with pembrolizumab or nivolumab in patients with advanced cancer, including liver cancer.

Learn more about this trial
NCI/CTEP #9782: A Phase I Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors

The study aims to:

- Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BMN 673 seven-day schedule in combination with carboplatin and paclitaxel.
- Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BMN 673 three-day schedule in combination with carboplatin and paclitaxel.
- Observe and record anti-tumor activity of BMN 673 in combination with carboplatin and paclitaxel. Although the clinical benefit of these drugs in combination has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability.

Learn more about this trial

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state.

Learn more